Pages that link to "Q51596506"
Jump to navigation
Jump to search
The following pages link to Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. (Q51596506):
Displaying 50 items.
- The "Statinth" wonder of the world: a panacea for all illnesses or a bubble about to burst (Q24796000) (← links)
- Pharmacologic plaque passivation for the reduction of recurrent cardiac events in acute coronary syndromes (Q28195424) (← links)
- Statins in the treatment of chronic heart failure: a systematic review (Q28200294) (← links)
- Effect of butyrolactone I on the producing fungus, Aspergillus terreus (Q30453685) (← links)
- Role of single photon emission computed tomography imaging in the evaluation of therapy for angina pectoris (Q30946248) (← links)
- All cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT. (Q31101617) (← links)
- HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data (Q32050110) (← links)
- Lipid-lowering therapy after coronary revascularization: the interventional cardiologist's perspective (Q32067070) (← links)
- Currently available hypolipidaemic drugs and future therapeutic developments (Q33485663) (← links)
- The JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: perspectives, outcomes, and consequences (Q33571213) (← links)
- Impact of dyslipidaemia. Lessons from clinical trials (Q33646056) (← links)
- Clinical positioning of HMG-CoA reductase inhibitors in lipid management protocols (Q33646070) (← links)
- Lipids and vascular disease: what we do and do not know (Q33746602) (← links)
- Efficacy of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for prevention of stroke (Q33815841) (← links)
- The evolving role of statins in the management of atherosclerosis (Q33818141) (← links)
- Prevention of coronary heart disease. Part I. Primary prevention (Q33859347) (← links)
- Feedback and hormonal regulation of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase: the concept of cholesterol buffering capacity (Q33899261) (← links)
- Lipid lowering improves endothelial functions (Q33944796) (← links)
- Current, new and future treatments in dyslipidaemia and atherosclerosis (Q33993678) (← links)
- Lipid-lowering therapy after coronary revascularization (Q34054446) (← links)
- Cardiac risk stratification: Role of the coronary calcium score (Q34068766) (← links)
- Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). AFCAPS/TexCAPS Research Group (Q34088640) (← links)
- Clinically relevant differences between the statins: implications for therapeutic selection (Q34093408) (← links)
- Re-emergence of fibrates in the management of dyslipidemia and cardiovascular risk (Q34107307) (← links)
- Beneficial effects of statins in coronary artery disease--beyond lowering cholesterol (Q34122524) (← links)
- Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials (Q34142678) (← links)
- Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors (Q34207135) (← links)
- Clinical context: current concepts of coronary heart disease management (Q34224519) (← links)
- HMG-CoA reductase inhibitors (Q34236671) (← links)
- Use of statins in CNS disorders (Q34300585) (← links)
- A new statin: a new standard. (Q34334884) (← links)
- Treatment of dyslipidemia in pre- and postmenopausal women with and without known atherosclerotic cardiovascular disease (Q34336846) (← links)
- Pharmacological effects of HMG CoA reductase inhibitors other than lipoprotein modulation (Q34373712) (← links)
- Treating lipid abnormalities in patients with type 2 diabetes mellitus (Q34491358) (← links)
- Documenting regression of atherosclerosis: practical approaches in drug development (Q34552563) (← links)
- Quantitative coronary angiography in regression trials: a review of methodologic considerations, endpoint selection, and limitations (Q34552571) (← links)
- Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial (Q34644974) (← links)
- Effect of HELP-LDL-apheresis on outcomes in patients with advanced coronary atherosclerosis and severe hypercholesterolemia (Q34663551) (← links)
- Disparity between angiographic regression and clinical event rates with hydrophobic statins (Q34714444) (← links)
- Who should receive HMG CoA reductase inhibitors? (Q34767394) (← links)
- Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin (Q34773911) (← links)
- Effects of lipids on thrombotic mechanisms in atherosclerosis (Q34990662) (← links)
- Prevention of stroke and dementia with statins: Effects beyond lipid lowering (Q35077221) (← links)
- Lovastatin extended release: a review of its use in the management of hypercholesterolaemia (Q35091923) (← links)
- Statin treatment and progression of atherosclerotic plaque burden (Q35100297) (← links)
- The complex interplay between cholesterol and prostate malignancy (Q35137013) (← links)
- Managing the spectrum of dyslipidemia in primary care (Q35215088) (← links)
- Barriers to preventive interventions for coronary heart disease (Q35585971) (← links)
- The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy (Q35692031) (← links)
- Primary hypercholesterolemia: genetic causes and treatment of five monogenic disorders (Q35696516) (← links)